Background: Various studies have demonstrated an increased risk for adult diseases in newborns born small-for-gestational-age (SGA). Adiponectin and resistin can be detected in cord blood and are suggested to affect insulin resistance (IR). This might represent a link between metabolic syndrome and SGA birth. Study Design: We investigated the relationship between the adipocytokines and inter-twin birth weight (BW) difference of 31 monozygotic twins with twin-twin transfusion syndrome; in 14 twin pairs BW difference was >15% (1 SGA twin, 1 appropriate-for-gestational-age, AGA, twin). Results: BW and length of all patients were positively related to adiponectin (r = 0.57; p < 0.0001; r = 0.47; p < 0.0001) and to resistin (r = 0.31; p < 0.01; r = 0.35; p < 0.01). In 71% (10/14), the SGA twins showed lower adiponectin concentrations than their AGA co-twins (only 6/14 for resistin). To correct for gestational age we calculated the relationship between the intrapair differences (Δ) of BW and Δ of the hormones. We found ΔBW positively correlated with adiponectin (r = 0.55; p < 0.001) but not with resistin (r = 0.22; p = 0.2). Δadiponectin was positively correlated with Δresistin (r = 0.45; p < 0.01). Conclusion: These data demonstrate that adiponectin and resistin levels are associated with BW with only adiponectin levels being reduced in SGA children independently of gestational age. Prenatally different metabolic status between the twins might predispose the SGA twin to develop IR later in life.

Keywords:
Small-for-gestational-age newborns, Twin-twin transfusion syndrome, Metabolic syndrome, Adiponectin, Resistin
1.
Kingdom JC, Bajoria R: Fetal assessment and management of labour in twin pregnancy. Recent Adv Obstet Gynecol 1998;20:65–80.
2.
Bajoria R, Kingdom JC: Chorionic plate vascular anatomy determines the efficacy of amnioreduction therapy for twin-twin transfusion syndrome. Hum Reprod 1998;13:1709–1713.
3.
Ville Y, Hyett J, Hecher K, Nicolaides K: Preliminary experience with endoscopic laser surgery for severe twin-twin transfusion syndrome. N Engl J Med 1995;332:224–227.
4.
Hecher K, Diehl W, Zikulnig L, Vetter M, Hackeloer BJ: Endoscopic laser coagulation of placental anastomoses in 200 pregnancies with severe mid-trimester twin-to-twin transfusion syndrome. Eur J Obstet Gynecol Reprod Biol 2000;92:135–139.
5.
Philipps AF, Rosenkrantz TS, Clark RM, Knox I, Chattin DG, Rays JR: Effect of fetal insulin deficiency on growth in fetal lambs. Diabetes 1991;40:20–27.
6.
Hofman PL, Cutfield WS, Robinson EM, Bergman RN, Menon RK, Sperling MA, Gluckman PD: Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrinol Metab 1997;82:402–406.
7.
Barker DJ, Hales CH, Osmond C, Clark PM: Type 2 diabetes mellitus non-insulin dependent, hypertension and hyperlipidemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36:62–67.
8.
Gluckman PD, Hanson M: The Fetal Matrix – Evolution, Development and Disease. Cambridge, Cambridge University Press, 2005, pp 103–117.
9.
Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB: Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. BMJ 2000;320:967–971.
10.
Koerner A, Kratsch J, Kiess W: Adipocytokines: leptin – the classical, resistin – the controversial, adiponectin – the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005;19:525–546.
11.
Matsuzawa Y, Funahashi T, Kihara S, Shimomura J: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2000;24:29–33.
12.
Yamamoto Y, Hirose H, Saito I, Niohikai K, Saruta T: Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 2004;89:87–90.
13.
Pardo IM, Geloneze B, Tambascia M, Barros-Filho A: Hyperadiponectinemia in newborns: relationship with leptin levels and birth weight. Obes Res 2004;12:521–524.
14.
Lindsay RS, Walker JD, Havel PJ, Hamilton BA, Calder AA, Johnstone FD: Scottish Multicentre Study of Diabetes Pregnancy 2003: adiponectin is present in cord blood but is unrelated to birth weight. Diabetes Care 2003;26:2244–2249.
15.
Corbetta S, Bulfamante G, Cortelazzi D, Barresi V, Cetin I, Mantovani G, Bondioni S, Beck-Peccoz P, Spada A: Adiponectin expression in human fetal tissues during mid- and late gestation J Clin Endocrinol Metab 2005;90:2397–2402.
16.
Pittas AG, Joseph NA, Greenberg AS: Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004;89:447–452.
17.
Sivan E, Mazaki-Tovi S, Pariente C, Efraty Y, Schiff E, Hemi R, Kanety H: Adiponectin in human cord blood: relation to birth weight and gender. J Clin Endocrinol Metab 2003;88:5656–5660.
18.
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Die T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman M, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–946.
19.
Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS: Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentration in healthy humans. J Clin Endocrinol Metab 2003;88:1730–1736.
20.
Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones RM, Zhu Q, Considine RV: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003;88:5452–5455.
21.
Fasshauer M, Paschke R: Regulation of adipocytokines and insulin resistance. Diabetologica 2003;46:1594–1603.
22.
Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ: Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003;149:331–335.
23.
Steppan C, Bailey S, Bhat S, Brown E, Banerjee R, Wright C, Patel H, Ahima R, Lazar M: The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.
24.
Lee JH, Chan JL, Yuannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros: Circulating resistin levels are not associated with obesity or insulin resistance in humans and were not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003;88:4848–4856.
25.
Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR: Relationship between serum resistin concentrations and insulin resistance in non-obese, obese and obese diabetic subjects. J Clin Endocrinol Metab 2004;89:1844–1848.
26.
Ng PC, Lee CH, Lam CW, Wong E, Chan IH, Fok TF: Plasma ghrelin and resistin concentrations are suppressed in infants of insulin-dependent diabetic mothers. J Clin Endocrinol Metab 2004;89:5563–5568.
27.
Ng PC, Lee CH, Lam CW, Chan IH, Wong E, Fok TF: Resistin in preterm and term newborns: relation to anthropometry, leptin, and insulin. Pediatr Res 2005;58:725–730.
28.
Kajantie E, Hytinantti T, Hovi P, Anderson S: Cord plasma adiponectin: a 20-fold rise between 24 weeks gestation and term. J Clin Endocrinol Metab 2004;89:4031–4036.
29.
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947–953.
30.
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–946.
31.
Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005–2010.
32.
Ouchi N, Kihara S, Arita Y, Okohama Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohomoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signalling through a cAMP-dependent pathway. Circulation 2000;102:1296–1301.
33.
Poulsen P, Levin K, Beck-Nielsen H, Vaag A: Age-dependent impact of zygosity and birth weight on insulin secretion and insulin action in twins. Diabetologia 2002;45:1649–1657.
34.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Hakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsu-bara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease in an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.
35.
Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao C, Chen CL, Tai TY, Chuang LM: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815–3819.
36.
Böttner A, Kratzsch J, Müller G, Kapellen TM, Blüher S, Keller E, Blüher M, Kiess W: Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004;89:4053–4061.
37.
Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S: Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet 1998;19:268–270.
38.
Gohlke BC, Huber A, Hecher K, Fimmers R, Bartmann P, Roth CL: Fetal insulin-like growth factor (IGF) I, IGF-II, and ghrelin in association with birth weight and postnatal growth in monozygotic twins with discordant growth. J Clin Endocrinol Metab 2005;90:2270–2274.
39.
Gohlke BC, Huber A, Bartmann P, Fimmers R, Hecher K, Bouret SG, Roth CL: Cord blood leptin and IGF-I in relation to birth weight differences and head circumference in monozygotic twins. J Pediatr Endocrinol Metab 2006;19:3–9.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.